Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-273P is a pseudogene of the U6 small nuclear RNA (snRNA) gene family in humans[7][8][13][15]. U6 snRNA itself is a highly conserved, uridine-rich RNA essential for the splicing of pre-messenger RNA as part of the spliceosome complex[5][3][14]. However, RNU6-273P does not produce a functional RNA; instead, it is a noncoding remnant, most likely generated through the retrotransposition or duplication of an ancestral U6 snRNA gene[13][15]. Such pseudogenes are common throughout the genome and do not code for proteins or functional RNAs. There is no evidence that RNU6-273P participates in regulatory mechanisms, acts as an RNA decoy, or has any clinical or biological significance[7][8][15]. U6 snRNA, the parental gene, is crucial for splicing and is one of the most conserved snRNAs in the eukaryotic genome[5][3]. U6 pseudogenes, including RNU6-273P, arise through molecular events like retrotransposition, and their sequences are maintained in the genome but generally lack promoter function or expression capacity[13][15]. According to genome databases (GeneCards, NCBI, BioGPS), RNU6-273P is listed as a pseudogene, and there is no evidence of disease association, protein product, or involvement in cellular pathways[7][8]. Most U6 snRNA pseudogenes are presumed to be transcriptionally inactive and nonfunctional[6][7]. Occasionally, some RNA pseudogenes can have regulatory functions through competitive endogenous RNA (ceRNA) activity, but this is not reported for RNU6-273P[4][10]. No reviewed literature links RNU6-273P to human disease, regulatory functions, or drug responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 273, pseudogene (RNU6-273P).